{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-224067","form_type":"8-K","ticker":"MPLT","cik":"0001770069","company_name":"MapLight Therapeutics, Inc.","filed_at":"2026-05-14T20:15:32+00:00","discovered_at":"2026-05-14T20:18:00.261608+00:00","generated_at":"2026-05-14T20:52:22.544429+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"MapLight Therapeutics Q1 net loss $60.7M; completes enrollment in two Phase 2 trials","bullets":["Net loss of $60.7M in Q1 2026 vs $22.3M YoY; R&D expenses $53.7M, G&A $10.8M.","Cash and investments $395.2M as of March 31, 2026; expected to fund operations through 2027.","Enrollment completed in Phase 2 ZEPHYR trial (schizophrenia, n=307); topline data expected mid-August 2026.","Last patient visit completed in Phase 2 IRIS trial (autism, n=161); topline data also expected mid-August 2026.","Phase 2 VISTA trial for Alzheimer's disease psychosis ongoing; topline expected H2 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-224067","json":"https://secwatch.observer/filing/0001193125-26-224067.json","markdown":"https://secwatch.observer/filing/0001193125-26-224067.md","text":"https://secwatch.observer/filing/0001193125-26-224067.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1770069/000119312526224067/0001193125-26-224067-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1770069/000119312526224067/mplt-20260514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T20:52:22.544429+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3cb261bafa0118086a9738cbf1c695e6842445f8","claim":"MapLight Therapeutics, Inc. reported first quarter ended March 31, 2026 results: net income Net loss was $60.7 million.","evidence_excerpt":"On May 14, 2026, MapLight Therapeutics, Inc. (the \"Company\") issued a press release announcing its financial results for the first quarter ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1770069/000119312526224067/0001193125-26-224067-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Net income","value":"Net loss was $60.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}